Anemia with CKD
Conditions
Interventions
None listed
Sponsors
Mitobe Yuko
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Patients aged 18 years or older at the time of informed consent (2) Patients receiving hemodialysis (including hemodiafiltration) 3 times a week for at least 12 weeks prior to informed consent (3) Patients receiving ESA treatment for at least 8 weeks prior to informed consent, and whose latest ESA treatment interval is within 4 weeks (4) Patients who have been administered the same type of ESA for at least 8 weeks prior to informed consent, and the administration interval and dose of the last two times are same (Epogin, Espo, and Epoetin Alfa Biosimilar are considered the same type of ESA) (5) Patients who are assessed to have no health problems for the participation in this study by principal investigator or co-investigators
Exclusion criteria
Exclusion criteria: (1) Patients with severe complications such as cerebral, hepatic, renal, cardiac, pulmonary, gastrointestinal, hematological, endocrine, metabolic or psychiatric disease (2) Those who have participated in other clinical trials involving medical devices or clinical research involving interventions within 12 weeks prior to this study (3) Patients judged to be unsuitable as research subjects by principal investigator or co-investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Correlation between ERI and serum hepcidin concentration | — |
Secondary
| Measure | Time frame |
|---|---|
| Research the correlation between subject background or various laboratory tests and serum hepcidin concentrations | — |
Contacts
Public ContactYuko Mitobe
Torii Pharmaceutical Co., Ltd.
Outcome results
None listed